# A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate

> **NCT00934648** · PHASE4 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 15 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** rituximab [MabThera/Rituxan]
- **DRUG:** methotrexate

## Key facts

- **NCT ID:** NCT00934648
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-10
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2014-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00934648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00934648, "A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00934648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*